Journal article
Comparison of fecal inflammatory markers in Crohn's disease
EK Wright, MA Kamm, P De Cruz, AL Hamilton, KJ Ritchie, JI Keenan, S Leach, L Burgess, A Aitchison, A Gorelik, D Liew, AS Day, RB Gearry
Inflammatory Bowel Diseases | Published : 2016
Abstract
Background: Fecal biomarkers are used increasingly to monitor Crohn's disease (CD). However, the relative accuracy of different markers in identifying inflammation has been poorly evaluated. We evaluated fecal calprotectin (FC), lactoferrin (FL), and S100A12 (FS) using endoscopic validation in a prospective study of the progression of CD after intestinal resection. Methods: Data were collected from 135 participants in a prospective, randomized, controlled trial aimed at preventing postoperative CD recurrence. Three hundred nineteen stool samples were tested for FC, FL, and FS preoperatively and 6, 12, and 18 months after resection. Colonoscopy was performed at 6 and/or 18 months. Endoscopic ..
View full abstractGrants
Funding Acknowledgements
AbbVie, Gutsy Group, Gandel Philanthropy, Angior Foundation, Crohn's Colitis Australia, and St Vincent's Research Endowment Fund provided research support. Bulhmann provided fCAL testing kits for Calprotectin. Techlab provided IBD EZ VUE Kits for Lactoferrin. The National Health and Medical Research Council (NHMRC) supported E. K. Wright, M. A. Kamm, and P. D. Cruz.